Revenues in USD of Nurix Therapeutics, Inc. from Q1 2019 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
Summary
Nurix Therapeutics, Inc. quarterly and annual Revenues history and change rate from Q1 2019 to Q1 2024.
  • Nurix Therapeutics, Inc. Revenues for the quarter ending 29 Feb 2024 was $16,585,000, a 30.7% increase year-over-year.
  • Nurix Therapeutics, Inc. Revenues for the twelve months ending 29 Feb 2024 was $80,887,000, a 94% increase year-over-year.
  • Nurix Therapeutics, Inc. annual Revenues for 2023 was $76,987,000, a 99.3% increase from 2022.
  • Nurix Therapeutics, Inc. annual Revenues for 2022 was $38,627,000, a 29.8% increase from 2021.
  • Nurix Therapeutics, Inc. annual Revenues for 2021 was $29,750,000, a 66.9% increase from 2020.
Revenues, Trailing 12 Months (USD)
Revenues, Quarterly (USD)
Revenues, YoY Quarterly Change (%)
Revenues, Annual (USD)
Revenues, YoY Annual Change (%)

Nurix Therapeutics, Inc. Quarterly Revenues (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $80,887,000 $16,585,000 +$3,900,000 +31% 01 Dec 2023 29 Feb 2024 10-Q 10 Apr 2024 2024 Q1
Q4 2023 $76,987,000 $15,159,000 +$8,376,000 +123% 01 Sep 2023 30 Nov 2023 10-K 15 Feb 2024 2023 FY
Q3 2023 $68,611,000 $18,467,000 +$7,676,000 +71% 01 Jun 2023 31 Aug 2023 10-Q 12 Oct 2023 2023 Q3
Q2 2023 $60,935,000 $30,676,000 +$19,244,000 +168% 01 Mar 2023 31 May 2023 10-Q 13 Jul 2023 2023 Q2
Q1 2023 $41,691,000 $12,685,000 +$3,064,000 +32% 01 Dec 2022 28 Feb 2023 10-Q 10 Apr 2024 2024 Q1
Q4 2022 $38,627,000 $6,783,000 -$613,000 -8.3% 01 Sep 2022 30 Nov 2022 10-K 15 Feb 2024 2023 FY
Q3 2022 $39,240,000 $10,791,000 +$539,000 +5.3% 01 Jun 2022 31 Aug 2022 10-Q 12 Oct 2023 2023 Q3
Q2 2022 $38,701,000 $11,432,000 +$4,341,000 +61% 01 Mar 2022 31 May 2022 10-Q 13 Jul 2023 2023 Q2
Q1 2022 $34,360,000 $9,621,000 +$4,610,000 +92% 01 Dec 2021 28 Feb 2022 10-Q 13 Apr 2023 2023 Q1
Q4 2021 $29,750,000 $7,396,000 +$707,000 +11% 01 Sep 2021 30 Nov 2021 10-K 09 Feb 2023 2022 FY
Q3 2021 $29,043,000 $10,252,000 +$6,167,000 +151% 01 Jun 2021 31 Aug 2021 10-Q 06 Oct 2022 2022 Q3
Q2 2021 $22,876,000 $7,091,000 +$2,909,000 +70% 01 Mar 2021 31 May 2021 10-Q 07 Jul 2022 2022 Q2
Q1 2021 $19,967,000 $5,011,000 +$2,147,000 +75% 01 Dec 2020 28 Feb 2021 10-Q 08 Apr 2022 2022 Q1
Q4 2020 $17,820,000 $6,689,000 +$4,827,000 +259% 01 Sep 2020 30 Nov 2020 10-K 16 Feb 2021 2020 FY
Q3 2020 $12,993,000 $4,085,000 -$6,495,000 -61% 01 Jun 2020 31 Aug 2020 10-Q 14 Oct 2021 2021 Q3
Q2 2020 $19,488,000 $4,182,000 -$5,257,000 -56% 01 Mar 2020 31 May 2020 10-Q 13 Jul 2021 2021 Q2
Q1 2020 $24,745,000 $2,864,000 -$6,370,000 -69% 01 Dec 2019 29 Feb 2020 10-Q 13 Apr 2021 2021 Q1
Q4 2019 $31,115,000 $1,862,000 01 Sep 2019 30 Nov 2019 10-K 16 Feb 2021 2020 FY
Q3 2019 $10,580,000 01 Jun 2019 31 Aug 2019 10-K 16 Feb 2021 2020 FY
Q2 2019 $9,439,000 01 Mar 2019 31 May 2019 10-K 16 Feb 2021 2020 FY
Q1 2019 $9,234,000 01 Dec 2018 28 Feb 2019 10-K 16 Feb 2021 2020 FY

Nurix Therapeutics, Inc. Annual Revenues (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $76,987,000 +$38,360,000 +99% 01 Dec 2022 30 Nov 2023 10-K 15 Feb 2024 2023 FY
2022 $38,627,000 +$8,877,000 +30% 01 Dec 2021 30 Nov 2022 10-K 15 Feb 2024 2023 FY
2021 $29,750,000 +$11,930,000 +67% 01 Dec 2020 30 Nov 2021 10-K 09 Feb 2023 2022 FY
2020 $17,820,000 -$13,295,000 -43% 01 Dec 2019 30 Nov 2020 10-K 28 Jan 2022 2021 FY
2019 $31,115,000 01 Dec 2018 30 Nov 2019 10-K 28 Jan 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.